Level of Vascular Endothelial Growth Factor in Aqueous Humor and Surgical Results of Ahmed Glaucoma Valve Implantation in Patients With Neovascular Glaucoma

被引:52
作者
Kim, Yong Guk [1 ]
Hong, Samin [1 ]
Lee, Christopher Seungkyu [1 ]
Kang, Sung Yong [1 ]
Seong, Gong Je [1 ]
Ma, Kyoung Tak [2 ]
Kim, Chan Yun [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Ophthalmol, Inst Vis Res, Seoul 120752, South Korea
[2] Siloam Eye Hosp, Dept Ophthalmol, Seoul, South Korea
关键词
Ahmed glaucoma valve; aqueous humor; neovascular glaucoma; vascular endothelial growth factor; BEVACIZUMAB;
D O I
10.1097/IJG.0b013e3181895e5c
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the associations between the levels of growth factors in aqueous humor and the surgical outcomes of Ahmed glaucoma valve implantation in patients with neovascular glaucoma (NVG). Methods: From 19 NVG eyes of 19 patients, a sample of aqueous humor was taken just before Ahmed glaucoma valve implantation. Levels of vascular endothelial growth factor (VEGF), transforming growth factor (TGF)-beta 1, and TGF-beta 2 in aqueous humor aspirates were measured using a sandwich enzyme-linked immunosorbent assay method. When the postoperative intraocular pressures were >= 21 mm Hg with or without antiglaucoma medications at 2 successive visits or when any other surgical interventions were needed to lower intraocular pressure, that surgery was considered a failure. After patients were classified into Success versus failure groups, the levels of the growth factors between the 2 groups was compared. The cumulative probability Of Success according to Kaplan-Meier analysis was also determined. Results: Mean postoperative follow-Lip period was 40.9 +/- 19.6 months and Cumulative probability of success was 43% at 57 months after surgery. Mean VEGF level in the failure group was higher than that of the success group (P = 0.014). However, there was no statistical difference in the levels of TGF-beta 1, TGF-beta 2, and protein between 2 study groups (all P > 0.05). Conclusions: The level of VEGF in aqueous humor was significantly higher in the failure group after the Ahmed glaucoma implantation compared with the success group. Our results imply that VEGF may play a role in determining surgical success after Ahmed valve implantation in patients with NVG.
引用
收藏
页码:443 / 447
页数:5
相关论文
共 12 条
[1]  
ADDICKS EM, 1983, ARCH OPHTHALMOL-CHIC, V101, P795
[2]  
Ayyala RS, 2001, OPHTHALMIC SURG LAS, V32, P248
[3]   Intracameral bevacizumab for iris rubeosis [J].
Grisanti, Salvatore ;
Biester, Sabine ;
Peters, Swaantje ;
Tatar, Olcay ;
Ziemssen, Focke ;
Bartz-Schmidt, Karl Ulrich .
AMERICAN JOURNAL OF OPHTHALMOLOGY, 2006, 142 (01) :158-160
[4]   Glaucoma drainage devices: A systematic literature review and current controversies [J].
Hong, CH ;
Arosemena, A ;
Zurakowski, D ;
Ayyala, RS .
SURVEY OF OPHTHALMOLOGY, 2005, 50 (01) :48-60
[5]   Intravitreal bevacizumab in a patient with neovascular glaucoma [J].
Kahook, MY ;
Schuman, JS ;
Noecker, RJ .
OPHTHALMIC SURGERY LASERS & IMAGING, 2006, 37 (02) :144-146
[6]  
Kay EDP, 1998, INVEST OPHTH VIS SCI, V39, P481
[7]   Pars plana vitrectomy and panretinal photocoagulation combined with trabeculectomy for successful treatment of neovascular glaucoma [J].
Kiuchi, Yoshiaki ;
Nakae, Kazuto ;
Saito, Yoshihiro ;
Ito, Shigeo ;
Ito, Nami .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2006, 244 (12) :1627-1632
[8]   Antifibrotics and wound healing in glaucoma surgery [J].
Lama, PJ ;
Fechtner, RD .
SURVEY OF OPHTHALMOLOGY, 2003, 48 (03) :314-346
[9]   Regression of neovascular iris vessels by intravitreal injection of bevacizumab [J].
Mason, John O., III ;
Albert, Michael A., Jr. ;
Mays, Andrew ;
Vail, Rachel .
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2006, 26 (07) :839-841
[10]   Transforming growth factor β2 levels in the aqueous humor in different types of glaucoma and the relation to filtering bleb development [J].
Picht, G ;
Welge-Luessen, U ;
Grehn, F ;
Lütjen-Drecoll, E .
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2001, 239 (03) :199-207